Showing results 15107 to 15126 of 19105
< previous
next >
| Preview | Issue Date | Title | Author(s) |
| 2014 | Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily | Hughes, T.; Hochhaus, A.; Kantarjian, H.; Cervantes, F.; Guilhot, F.; Niederwieser, D.; Le Coutre, P.; Rosti, G.; Ossenkoppele, G.; Lobo, C.; Shibayama, H.; Fan, X.; Menssen, H.; Kemp, C.; Larson, R.; Saglio, G. |
| 2023 | Safety and Efficacy of Tenecteplase and Alteplase in Patients With Tandem Lesion Stroke: A Post-Hoc Analysis of the EXTEND-IA TNK Trials | Yogendrakumar, V.; Churilov, L.; Mitchell, P.J.; Kleinig, T.J.; Yassi, N.; Thijs, V.; Wu, T.; Shah, D.; Bailey, P.; Dewey, H.M.; Choi, P.M.; Ma, A.; Wijeratne, T.; Garcia-Esperon, C.; Cloud, G.; Chandra, R.V.; Cordato, D.J.; Yan DMedSc, B.; Sharma, G.; Desmond, P.M.; et al. |
| 2014 | Safety and efficacy of topical bacteriophage and ethylenediaminetetraacetic acid treatment of Staphylococcus aureus infection in a sheep model of sinusitis | Drilling, A.; Morales, S.; Boase, S.; Jervis-Bardy, J.; James, C.; Jardeleza, C.; Tan, N.; Cleland, E.; Speck, P.; Vreugde, S.; Wormald, P. |
| 2022 | Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studies. | Marshall, H.S.; Vesikari, T.; Richmond, P.C.; Wysocki, J.; Szenborn, L.; Beeslaar, J.; Maguire, J.D.; Balmer, P.; O'Neill, R.; Anderson, A.S.; Prégaldien, J.-L.; Maansson, R.; Jiang, H.-Q.; Perez, J.L. |
| 2019 | Safety and immunogenicity of MF59-adjuvanted cell culture-derived A/H5N1 subunit influenza virus vaccine: dose-finding clinical trials in adults and the elderly | Frey, S.E.; Shakib, S.; Chanthavanich, P.; Richmond, P.; Smith, T.; Tantawichien, T.; Kittel, C.; Jaehnig, P.; Mojares, Z.; Verma, B.; Kanesa-Thasan, N.; Hohenboken, M. |
| 2011 | Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study | Kotasek, D.; Tebbutt, N.; Desai, J.; Welch, S.; Siu, L.; McCoy, S.; Sun, Y.; Johnson, J.; Adewoye, A.; Price, T. |
| 2008 | Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours | Price, T.; Lipton, L.; McGreivy, J.; McCoy, S.; Sun, Y.; Rosenthal, M. |
| 2020 | Safety and protective effects of maternal influenza vaccination on pregnancy and birth outcomes: A prospective cohort study | Mohammed, H.; Roberts, C.T.; Grzeskowiak, L.E.; Giles, L.C.; Dekker, G.A.; Marshall, H.S. |
| 2019 | Safety and tolerability of bacteriophage therapy for chronic rhinosinusitis due to staphylococcus aureus | Ooi, M.L.; Drilling, A.J.; Morales, S.; Fong, S.; Moraitis, S.; MacIas-Valle, L.; Vreugde, S.; Psaltis, A.J.; Wormald, P.J. |
| 2014 | Safety evaluation of a sinus surfactant in an explant-based cytotoxicity assay | Tan, N.; Cooksley, C.; Paramasivan, S.; Vreugde, S.; Wormald, P. |
| 2007 | Safety of 96-hour incision-site continuous infusion of ropivacaine for postoperative analgesia after bowel cancer resection | Corso, O.; Morris, R.; Hewett, P.; Karatassas, A. |
| 2022 | Safety of Ceasing Aspirin Used Without a Clinical Indication After Age 70 Years: A Subgroup Analysis of the ASPREE Randomized Trial | Nelson, M.R.; Polekhina, G.; Woods, R.L.; Reid, C.M.; Tonkin, A.M.; Wolfe, R.; Murray, A.M.; Kirpach, B.; Ernst, M.E.; Lockery, J.E.; Shah, R.C.; Stocks, N.; Orchard, S.G.; Zhou, Z. |
| 2020 | Safety of meningococcal B vaccine (4CMenB) in adolescents in Australia | Marshall, H.S.; Koehler, A.P.; Wang, B.; A'Houre, M.; Gold, M.; Quinn, H.; Crawford, N.; Pratt, N.; Sullivan, T.R.; Macartney, K. |
| 2012 | Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients | Lee, S.; Roberts, S.; Berak, H.; Dusheiko, G.; Harley, H.; Gane, E.; Husa, P.; Horsmans, Y.; Hadziyannis, S.; Jenny Heathcote, E.; Messinger, D.; Tatsch, F.; Han, K.; Ferenci, P. |
| 2014 | Safety of varenicline tartrate and counseling versus counseling alone for smoking cessation: a randomized controlled trial for inpatients (STOP Study) | Carson, K.; Smith, B.; Brinn, M.; Peters, M.; Fitridge, R.; Koblar, S.; Jannes, J.; Singh, K.; Veale, A.; Goldsworthy, S.; Litt, J.; Edwards, D.; Hnin, K.; Esterman, A. |
| 2015 | Safety profile of a miniaturized insertable cardiac monitor: results from two prospective trials | Mittal, S.; Sanders, P.; Pokushalov, E.; Dekker, L.; Kereiakes, D.; Schloss, E.; Pouliot, E.; Franco, N.; Zhong, Y.; Di Bacco, M.; Pürerfellner, H. |
| 2020 | Safety profile of a multi-antigenic DNA vaccine against hepatitis C virus | Gummow, J.; Masavuli, M.; Mekonnen, Z.A.; Li, Y.; Wijesundara, D.K.; Shrestha, A.C.; Voskoboinik, I.; Gowans, E.J.; Grubor-Bauk, B. |
| 2020 | Safety Profile of Slit-Lamp-Delivered Retinal Laser Photobiomodulation | Ao, J.; Chidlow, G.; Wood, J.P.; Casson, R. |
| 2020 | SAFety, Effectiveness of care and Resource use among Australian Hospitals (SAFER Hospitals): a protocol for a population-wide cohort study of outcomes of hospital care | Ranasinghe, I.; Hossain, S.; Ali, A.; Horton, D.; Adams, R.J.; Aliprandi-Costa, B.; Bertilone, C.; Carneiro, G.; Gallagher, M.; Guthridge, S.; Kaambwa, B.; Kotwal, S.; O'Callaghan, G.; Scott, I.A.; Visvanathan, R.; Woodman, R.J. |
| 2010 | SAGE analysis of genes differentially expressed in presymptomatic TgSOD1(G93A) transgenic mice identified cellular processes involved in early stage of ALS pathology | Guipponi, M.; Li, Q.; Hyde, L.; Beissbarth, T.; Smyth, G.; Masters, C.; Scott, H. |
